With a new CEO at the helm, Swiss CDMO Lonza is looking to revivify its business by doubling down on contract manufacturing ...

Recent developments in the health sector include a dosing pause in Keros Therapeutics' drug trial, Corcept Therapeutics' ALS ...

By Isabel Demetz (Reuters) -Swiss contract drugmaker Lonza plans to simplify its structure and exit its capsules and health ...

Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development ...

Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin EElevation Oncology nominates a novel HER3 ADC candidate EO-1022 ...

Swiss healthcare manufacturing organization Lonza saw its shares rise 7% to 559.40 francs in early trading, as it announced ...

Investing.com -- Lonza’s shares rose over 6% on Thursday following the company’s announcement of plans to divest its Capsules ...

Swiss contract drugmaker Lonza plans to exit its capsules and health ingredients (CHI) business, it said on Thursday, after ...

The life-sciences company will focus on its core business, including drug development, with restructuring and a divestment ...

Lonza Group AG / Key word (s): Strategic Company Decision Lonza Investor Update 2024 Outlines Strategy, New Organizational Structure and Guidance 12-Dec-2024 / 06:25 CET/CEST Release of an ad hoc ...

Lonza Group Ltd (GB:0QNO) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...

Lonza Group AG (OTCMKTS:LZAGY – Free Report) – William Blair lowered their FY2025 EPS estimates for Lonza Group in a research ...